PRECLINICAL ASSESSMENT OF DUAL ERBB1/ERBB2 TARGETING AS A POTENTIAL ADJUVANT MOLECULAR THERAPY FOR INTRAHEPATIC CHOLANGIOCARCINOMA

被引：0
|
作者：
Sirica, Alphonse E. [1 ]
Zhang, Zichen [1 ]
Campbell, Deanna J. [1 ]
机构：
[1] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
221
引用
收藏
页码：408A / 408A
页数：1
相关论文
共 50 条
  • [21] Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review
    Patnaik, Sunil Kumar
    Chandrasekar, M. J. N.
    Nagarjuna, Palathoti
    Ramamurthi, Deepthi
    Swaroop, Akey Krishna
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (22) : 2831 - 2846
  • [22] Spatial Structure of the Transmembrane Domain Heterodimer of ErbB1 and ErbB2 Receptor Tyrosine Kinases
    Mineev, Konstantin S.
    Bocharov, Eduard V.
    Pustovalova, Yulia E.
    Bocharova, Olga V.
    Chupin, Vladimir V.
    Arseniev, Alexander S.
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 400 (02) : 231 - 243
  • [23] Does Lrig1 expression have a relationship with ERBB1 and ERBB2 expression in schizophrenia?
    Uzuncakmak, Sevgi Karabulut
    Ozcan, Halil
    Aydin, Pelin
    Halici, Zekai
    CUKUROVA MEDICAL JOURNAL, 2025, 50 (01): : 221 - 230
  • [24] Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D
    Yang, Lu
    Li, Yun
    Bhattacharya, Arup
    Zhang, Yuesheng
    ONCOTARGET, 2016, 7 (27) : 42340 - 42352
  • [25] Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer
    Singla, Smit
    Pippin, James A.
    Drebin, Jeffrey A.
    ONCOLOGY REPORTS, 2012, 28 (06) : 2211 - 2216
  • [26] Growth inhibitory effects and mechanisms of lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinase, in gastric cell lines
    Kim, J. W.
    Im, S. A.
    Kim, H. P.
    Oh, D. Y.
    Kim, T. Y.
    Bang, Y. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 262 - 262
  • [27] Virtual high throughput screening of natural peptides against ErbB1 and ErbB2 to identify potential inhibitors for cancer chemotherapy
    Patnaik, Sunil Kumar
    Ayyamperumal, Selvaraj
    Jade, Dhananjay
    Palathoti, Nagarjuna
    Akey, Krishna Swaroop
    Jupudi, Srikanth
    Harrison, Michael A.
    Ponnambalam, Sreenivasan
    Nanjan, M. J.
    Chandrasekar, M. J. N.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (11): : 5551 - 5574
  • [28] ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site
    Jansen, Suzanne M.
    Sleumer, Laura S.
    Damen, Ester
    Meijer, Inez M. J.
    van Zoelen, Everardus J. J.
    van Leeuwen, Jeroen E. M.
    CELLULAR SIGNALLING, 2009, 21 (05) : 810 - 818
  • [29] Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2
    Patnaik, Sunil Kumar
    Swaroop, Akey Krishna
    Naik, Mudavath Ravi
    Selvaraj, Jubie
    Chandrasekar, Moola Joghee Nanjan
    DRUG RESEARCH, 2023, 73 (06) : 341 - 348
  • [30] erbB1/HER1和erbB2/HER2在肺癌的表达
    邓在春
    俞文英
    胡国平
    郑如恒
    张敦华
    谭云山
    徐永华
    江万里
    现代实用医学, 2001, (11) : 539 - 541
12345